JPRN-UMIN000010355
Completed
未知
A study to assess the efficacy, safety, pharmacokinetics, and related polymorphism of medicines for pulmonary arterial hypertension in pediatric patients - A study to assess the efficacy, safety, pharmacokinetics, and related polymorphism of medicines for pulmonary arterial hypertension in pediatric patients
Department of clinical pharmacology and genetics, school of pharmaceutical science, university of Shizuoka graduate school0 sites100 target enrollmentApril 1, 2013
ConditionsPulmonary arterial hypertension
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Pulmonary arterial hypertension
- Sponsor
- Department of clinical pharmacology and genetics, school of pharmaceutical science, university of Shizuoka graduate school
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •No exclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A study to assess the efficacy, safety, pharmacokinetics and related genetic polymorphisms of sunitinibrenal cell carcinomaJPRN-UMIN000015553Department of Pharmacy, Gifu University Hospital50
Completed
Not Applicable
A study to assess the efficacy, safety, pharmacokinetics and related genetic polymorphisms of afatinibadenocarcinoma of the lungJPRN-UMIN000014237aboratoly of Pharmacy Practice and Social Science, Gifu Pharmaceutical University43
Not yet recruiting
Not Applicable
Alternative treatment to treatment nonresponsive leprosyHealth Condition 1: A305- Lepromatous leprosyCTRI/2022/09/045483Prof Nusrat Shafiq
Completed
Phase 2
Active phase study of MD-0901 in pediatric ulcerative colitis.Mildly to moderately active ulcerative colitisJPRN-jRCT2080223746MOCHIDA PHARMACEUTICAL CO., LTD26
Completed
Phase 2
Maintenance phase study of MD-0901 in pediatric ulcerative colitis.lcerative colitis in remissionJPRN-jRCT2080223747MOCHIDA PHARMACEUTICAL CO., LTD26